IRAK4 Inhibitors – Target Pipeline List 06/2019
Targets: IRAK4; interleukin-1 receptor-associated kinase 4
This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.
IRAK4 (interleukin-1 receptor-associated kinase 4) is a key protein kinase in innate immune cells. Toll-Like Receptor (TLR) and Interleukin-1 Receptors (IL-1R) signalling via the adaptor protein myeloid differentiation factor 88 (MYD88) results in activation of IRAK4 which in turn results in downstream production of pro-inflammatory cytokines through NF-KB and mitogen-activated protein kinase (MAPK) activation. Inhibition of IRAK4 function is validated as a means of treating cytokine-driven autoimmune and inflammatory conditions.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.